Harmony Biosciences Holdings, Inc. (HRMY) — Fair Value Analysis

Base-case fair value (P50): $35.08 · Current price: $31.36 · Verdict: Fairly Valued

The Verdict on HRMY

HARMONY BIOSCIENCES HLDG INC (HRMY) is currently assessed as Fairly Valued based on our latest Monte Carlo simulations. With a current price of $32.34, HRMY trades at a discount to its median fair value (P50) of $35.86. This represents a potential upside of +10.9% from current levels. The Fairly Valued verdict indicates that the market's current pricing largely aligns with our probabilistic fair value models, suggesting HRMY is neither significantly overvalued nor undervalued at this time. The +10.9% difference underscores a balanced risk-reward profile, with limited overvaluation risk for the company given its current fundamentals and market price of $32.34.

How HRMY stacks up against peers

HRMY boasts a "strong" quality tier, signaling robust operational and financial health when benchmarked against its sector peers. This strong underlying quality provides a solid foundation that supports its median fair value (P50) of $35.86, reflecting the company's fundamental strength. The strong standing in its sector helps explain why its current price of $32.34 is not drastically disconnected from its calculated fair value, suggesting fundamental stability. While the current price is slightly below the P50, this "strong" quality tier implies resilience and potentially justifies the modest +10.9% upside, differentiating it favorably from lower-quality competitors within its sector.

What this means for investors

Investors analyzing HRMY should note the calculated +10.9% upside from the current price of $32.34 to the median fair value (P50) of $35.86. This gap suggests that while the stock is not deeply discounted, it offers a measured potential return based on our Monte Carlo analysis. The overall verdict of Fairly Valued is further supported by HRMY's "strong" quality tier, indicating a sound underlying business. For a deeper understanding of HRMY's risk-reward profile, including detailed bear-case and bull-case scenarios across the full Monte Carlo distribution, sign up for a free FairCurve account. Track HRMY's fair value as new fundamentals are released and gain deeper insights.